Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hoxc13 overexpression in skin

ABSTRACT: A study of the effects of Hoxc13 overexpression in skin using Hoxc13 transgenic mice (GC13) known to develop severe hair growth defects and alopecia. Total skin from GC13 mice 5 dpn is compared to total skin from normal FVB mice 5 dpn using Affymetrix HG-U74Av2 GeneChips. Keywords: repeat sample

ORGANISM(S): Mus musculus

PROVIDER: GSE2374 | GEO | 2006/03/07

SECONDARY ACCESSION(S): PRJNA91529

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of skin from wild type and Hoxc13 transgenic mice to investigate their propensity to develop severe hair growth defects and alopecia

Project description:A study of the effects of Hoxc13 overexpression in skin using Hoxc13 transgenic mice (GC13) known to develop severe hair growth defects and alopecia. Total skin from GC13 mice 5 dpn is compared to total skin from normal FVB mice 5 dpn using Affymetrix HG-U74Av2 GeneChips.

2007-12-04 | E-GEOD-2374 | biostudies-arrayexpress

Differential gene expression profile in skin of Hoxc13 gene-targeted mice

Project description:Hoxc13 has been shown to be essential for proper hair shaft differentiation as Hoxc13 gene-targeted (Hoxc13tm1Mrc) mice completely lack external hair. Because of the phenotypic parallels to the Foxn1nu (nude) mutant mice, we tested whether Hoxc13 and Foxn1 act in a common pathway of hair follicle (HF) differentiation. We show that the alopecia exhibited by both the Hoxc13tm1Mrc and Foxn1nu mice is due to strikingly similar defects in hair shaft differentiation and that both mutants suffer from a severe nail dystrophy. These similarities are consistent with the overlap of Hoxc13 and Foxn1 expression patterns in the HF and nail matrix. DNA microarray analysis of scapular skin from Hoxc13tm1Mrc mutant (mut) compared to wild type (wt) mice identified Foxn1 as significantly down-regulated along with numerous hair keratin genes. This Foxn1 down-regulation apparently reflects the loss of direct transcriptional control by HOXC13 as indicated by our results obtained through co-tranfection and chromatin immunoprecipitation (ChIP) assays. Total number of samples was 6. The experiment was perfomed in triplicate involving 3 indendent wild type skin samples (sample 1, 2, and 3) and 3 independent mutant skin samples (sample 4, 5, and 6).

2010-08-25 | E-GEOD-23759 | biostudies-arrayexpress

Differential gene expression profile in skin of Hoxc13 gene-targeted mice

2010-08-25 | GSE23759 | GEO

Human skin specific long noncoding RNA HOXC13-AS regulates keratinocyte differentiation by inferfering with Golgi-ER retrograde transport

Project description:In an RNAseq analysis, we have identified the HOXC13-AS significantly downregulated in wound biopsies and epidermal cells compared to skin counterparts. To study the genes regulated by HOXC13-AS, we transfected HOXC13-AS siRNA pool into human primary epidermal keratinocytes to knockdown HOXC13-AS and induced cell differentiation for 3 days by 1.5 mM calcium. We performed a global transcriptome analysis of keratinocytes upon the HOXC13-AS knockdown using Affymetrix arrays.

2022-06-15 | GSE206103 | GEO

Mus musculus

Project description:Hoxc13 overexpression in skin

| PRJNA91529 | ENA

First ruxolitinib treatment of human alopecia areata patients

Project description:Two patients with alopecia areata were treated with systemic ruxolitinib. Skin biopsies were taken before starting treatment and 12 weeks after starting treatment. We used microarrays to assess changes in gene expression of affected skin before and after starting treatment Two patients with alopecia areata were recruited for our study. Skin biopsies of affected scalp were taken prior to starting treatment with oral ruxolinitib. Additional skin biopsies were taken 12 weeks after starting treatment. Scalp skin biopsies were taken from patients without alopecia areata for comparison. RNA was extracted, cDNA libraries were made and profiled on affymetrix microarray chips.

2014-08-17 | E-GEOD-58573 | biostudies-arrayexpress

Transgenic overexpression of Pla2g2f at a level relevant to skin pathology display alopecia and psoriasis-like epidermal hyperplasia

Project description:Pla2g2f is dominantly expressed in the suprabasal layer of mouse epidermis. Microarray gene profiling supported the overall tendency of epidermal and sebaceous gland hyperplasia as well as alopecia in Pla2g2f-transgenic skin. Pla2g2f-Tg/+ mice and littermate controls (C57BL/6 background); 25-day old; skin; pooled from 4 mice for each genotype.

2015-08-08 | E-GEOD-71829 | biostudies-arrayexpress

Treatment of C3H/HeJ grafted mice with baricitinib [prevention]

Project description:The C3H/HeJ grafted model of alopecia areata was used to determine the efficacy of systemic baricitinib at preventing alopecia or treating established disease. The efficacy of topical baricitinib at treating established alopecia in the C3H/HeJ grafted model was also assessed. Microarrays were performed on skin RNA at week 0 and week 12 after starting treatment in all models. Baricitinib was administered in systemic form at the time of grafting. Skin samples were taken after 12 weeks.

2015-05-01 | E-GEOD-61551 | biostudies-arrayexpress

Treatment of C3H/HeJ grafted mice with baricitinib [systemic]

Project description:The C3H/HeJ grafted model of alopecia areata was used to determine the efficacy of systemic baricitinib at preventing alopecia or treating established disease. The efficacy of topical baricitinib at treating established alopecia in the C3H/HeJ grafted model was also assessed. Microarrays were performed on skin RNA at week 0 and week 12 after starting treatment in all models. Baricitinib was administered in systemic form after disease establishment. Skin samples were taken at the start of treatment and after 12 weeks.

2015-05-01 | E-GEOD-61552 | biostudies-arrayexpress

Treatment of C3H/HeJ grafted mice with baricitinib [topical]

Project description:The C3H/HeJ grafted model of alopecia areata was used to determine the efficacy of systemic baricitinib at preventing alopecia or treating established disease. The efficacy of topical baricitinib at treating established alopecia in the C3H/HeJ grafted model was also assessed. Microarrays were performed on skin RNA at week 0 and week 12 after starting treatment in all models. Baricitinib was administered in topical form after disease establishement. Skin samples were taken at the start of treatment and after 12 weeks.

2015-05-01 | E-GEOD-61554 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data